SPC152
3-[5-(2-Flúorfenýl)-[1,2,4]oxadíasól-3-ýl]-bensósýra (Ataluren)
Status:
VeittApplication date:
27.4.2016Application published:
15.5.2016Grant published:
15.12.2019
Max expiry date:
4.8.2029Medicine name:
TranslarnaMedicine for children:
No
Timeline
Today
27.4.2016Application
15.5.2016Publication
15.12.2019Registration
4.8.2029Expires
Marketing license
IS authorization number:
EU/1/13/902/001-003Date:
15.8.2014
Foreign authorization number:
EU/1/13/902Date:
31.7.2014
Owner
Name:
PTC Therapeutics, Inc.Address:
100 Corporate Court, Middlesex Business Center, South Plainfield US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2076501